Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 7/20 | 0.75 |
| ▸ | ACHE | P22303 | 6/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30105291 | 1.00 | BCHE (0.75) | BCHEACHE | |
| SCHEMBL7046057 | 1.00 | BCHE (0.75) | BCHEACHE | |
| SCHEMBL7045560 | 1.00 | BCHE (0.75) | BCHEACHE | |
| Bromide SCHEMBL7927268 | 0.98 | BCHE (0.76) | BCHEACHE | |
| Ammonia Solution, Strong SCHEMBL28709118 | 0.98 | BCHE (0.71) | BCHEACHE | |
| Bromide SCHEMBL2401340 | 0.98 | BCHE (0.76) | BCHEACHE | |
| Bromide SCHEMBL7927418 | 0.98 | BCHE (0.76) | BCHEACHE | |
| SCHEMBL5393053 | 0.97 | BCHE (0.70) | BCHEACHE | |
| Bromide SCHEMBL7919286 | 0.95 | BCHE (0.71) | BCHEACHE | |
| SCHEMBL31232300 | 0.90 | BCHE (0.65) | BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10272103-B2 | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants | RELYPSA, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| EP-2998329-A2 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | Relypsa, Inc. (US) | 2016-03-23 | — | — | EP | disclosed |
| US-20160051576-A1 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. (US) | 2016-02-25 | — | — | US | disclosed |
| US-9181364-B2 | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants | RELYPSA, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| EP-2539380-B1 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-20130022570-A1 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| EP-2539380-A2 | CROSSLINKED POLYVRNYLAMINE, POLY ALL YLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | Relypsa, Inc. (US) | 2013-01-02 | — | — | EP | disclosed |
| WO-2011106542-A2 | CROSSLINKED POLYVRNYLAMINE, POLY ALL YLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160051576-A1 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | NR1H4, SLC10A2, GPBAR1 | BCHE 189/4885ACHE 3020/4885 |
| US-10272103-B2 | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants | NR1H4, SLC10A2, GPBAR1 | BCHE 189/4885ACHE 3020/4885 |
| US-20130022570-A1 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | NR1H4, SLC10A2, GPBAR1 | BCHE 189/4885ACHE 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.